About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT

By: via GlobeNewswire

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., an innovator in high-throughput spatial multiomics technologies designed to advance precision medicine, today announced key development milestones for its G4X™ Spatial Sequencer at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida.

G4X Early Access Program Ongoing and Broader Availability on Track

The G4X Early Access Program is currently underway at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback highlighting the platform’s real-world potential.

“As the first early access site, we’ve had the chance to appreciate the impact of the very high throughput of the G4X, along with its ability to generate high-quality data across multiple sample types, right from the start,” said Dr. Ioannis Vlachos, Director of the Spatial Technologies Unit (www.spatialtechnology.org) at Beth Israel Deaconess Medical Center, and Associate Professor of Pathology at Harvard Medical School. “The system’s higher throughput is squarely aligned with current needs of the spatial biology field, where increased sample volumes and lower turnaround times can enable larger studies, adoption into translational or clinical trial settings, as well as higher return-of-investment and reduced costs for researchers and core facilities.”

“We’re excited to have the G4X in our lab, and the data we’ve seen so far is promising for our work with the Human Tumor Atlas Network,” said Dr. Tae Hwang, Founding Director of the Molecular Artificial Intelligence Initiatives at Vanderbilt University Medical Center. “The reproducibility, speed, and cost-efficiency allow us to scale 3D spatial analyses in larger retrospective clinical cohorts. Integrating the high-throughput spatial multimodal analysis of samples on G4X with AI can provide us critical insights into disease mechanisms and therapeutic biomarkers, ultimately advancing patient care.”

Singular plans to expand its early access program to a few more sites in Q2. Meanwhile, pre-orders for the G4X are now open, and initial shipments are on track for June 2025. Researchers wishing to start generating multiomic data can use Singular’s technology access services in the meantime.

“The G4X data we received back from Singular on our head and neck cancer sample cohort was highly informative,” remarked Dr. Shanye Yin, Assistant Professor in the Department of Pathology at Albert Einstein College of Medicine and Director of the Pathology Single-Cell Core Laboratory. “Integrating transcript, protein, and fH&E data allowed us to identify cell populations and complex tumor-immune interactions with single-cell precision. Additionally, the system's robustness is confirmed as the results are fully validated by other multi-plex imaging platforms.”

Exceptional Multiomic Performance and 3D Reconstruction Showcased

At AGBT, Singular Genomics presented data demonstrating the G4X platform’s robust integrated multiomic performance. Immune-oncology-focused lung, kidney, colon, and breast panels showed high sensitivity, specificity, and reproducibility in FFPE samples, providing comprehensive spatial insights into cancerous and healthy tissues.

Building on these data, Singular showcased advanced 3D multi-omic reconstruction and niche detection from 10 serial renal cell carcinoma FFPE sections, over 6.2 million cells, and 438 million transcripts—all from a single G4X flow cell.

“The high throughput on the G4X ensures exceptional consistency across FFPE samples, while simultaneously measuring transcripts, proteins, and fH&E within the same sample provides strong reproducibility across modalities. This unique combination makes 3D reconstruction surprisingly straightforward,” said Michael Lawson, Director, R&D at Singular Genomics. “Analyzing tissues in a higher dimension facilitates advanced spatial neighborhood analyses of immune-tumor interactions, something we believe will translate into more robust biomarker identification.”

Additional Highlights

  • Direct Sequencing in Tissues: Singular advanced its proprietary Direct-Seq technology, enabling the sequencing of variable regions within cells in tissue. During AGBT, the company demonstrated accurate T- and B-cell receptor sequencing in FFPE tonsil samples.
  • Data Availability: Researchers can access raw and demo datasets from Singular’s multi-tissue performance studies to explore the platform’s capabilities and validate real-world spatial data.

About Singular 
Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4® Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In addition, the Company is currently developing the G4X™ Spatial Sequencer, which will leverage its proprietary sequencing technology, applying it as an in situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine. Visit www.singulargenomics.com for more information.

Media Contact
Darius Fugere
dariusf@singulargenomics.com


Primary Logo

More News

View More
3 Defense Stocks Surging as Ukraine Tensions Deepen
Via MarketBeat
Topics Government
Tickers BAESY RNMBY SAABY
Starbucks Stock Slumps; This Competitor Shows Strength
Via MarketBeat
Tickers BROS SBUX
The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead
Via MarketBeat
Tickers AMZN GOOG GOOGL TTD
Are Airline Stocks Ready for Takeoff After a Turbulent 2025?
Via MarketBeat
Topics Economy
Tickers AAL DAL LUV XTN
Why the Precious Metal Nobody Talks About Could Be Your Best Bet
Via MarketBeat
Topics ETFs Economy
Tickers PALL VOO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.